Vaxcyte appoints Dr. Carlos Paya to its Board of Directors as Chair alongside Dr. Michael Kamarck joining as Board member

– USA, CA –  Vaxcyte, Inc. (Nasdaq: PCVX) today announced the appointments of accomplished industry leaders Dr. Carlos Paya (MD, Ph.D.) and Dr. Michael Kamarck (Ph.D.) to its board of directors.

Dr. Paya will also serve as the Board Chair replacing longtime director Kurt von Easter who served as Interim Chair and will remain on the board.

“We are pleased to have Carlos and Michael join our board of directors to help us scale and advance our business to deliver next-generation vaccines, including VAX-24, our 24-valent pneumococcal conjugate vaccine candidate,” said CEO, Grant Pickering. “Carlos, our new Chair, and Michael bring deep biopharmaceutical and vaccine expertise and will provide strategic insights across many aspects of our business, including R&D, commercialization, supply chain and manufacturing, as they have done for numerous companies.”

About Dr. Carlos Paya

Dr. Paya’s esteemed career spans over 30 years as a leading physician-scientist in immunology and a senior executive in the biopharmaceutical industry. He has broad leadership expertise in R&D, commercial readiness, and product launches. Dr. Paya currently holds several board positions and serves as the Board Chairman for Fluidigm and Highlight Therapeutics. Most recently, Dr. Paya served as the CEO and President of Immune Design Corp., as they advanced their dual platforms focused on vaccine adjuvants and cancer immunotherapies, culminating in the company’s acquisition by Merck. Previously, he was the President of Elan Pharmaceuticals responsible for the Biopharmaceutical unit focused on neuroscience. In this role, he partnered with Biogen Idec to support the global marketing and sales strategy for Tysabri®. Dr. Paya spent several years at Eli Lilly in roles of increasing responsibility, including Global Head for the Diabetes and Endocrine Franchise. He started his career in academics as a Professor of Medicine, Immunology, and Pathology at the Mayo Medical School. During his tenure at the Mayo Clinic, Dr. Paya served as the Vice Dean for the Clinical Investigation Program.

“Vaxcyte is working to bring transformative innovation to vaccine development with the potential to achieve what other approaches have been unable to deliver,” commented Dr. Paya. “I’m pleased to join in their effort to advance novel and superior vaccines for some of the most common and deadly infectious diseases worldwide, including pneumococcal disease for which the need for broader-spectrum vaccines continues to be critical.”

Dr. Paya has a M.D. and Ph.D. from Complutense University of Madrid.

About Dr. Michael Kamarck

Dr. Kamarck’s career in biopharmaceuticals spans over 35 years and includes senior executive positions at multiple leading pharmaceutical companies, as well as extensive expertise in product development and manufacturing. He is a global authority on the scale-up and commercialization of pneumococcal conjugate vaccines. He is the Chairman of the Sanofi Biotech Advisory Council, providing strategic guidance to advance Sanofi’s biologicals business. Dr. Kamarck recently retired as CTO for Vir Biotechnology, Inc., following more than four years leading a multi-modality technical approach to the development of treatments for serious infectious diseases such as COVID-19 (sotrovimab), influenza, and hepatitis B. Previously, Dr. Kamarck was the SVP of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures. In this role, he was responsible for the worldwide manufacturing network in support of the vaccine portfolio and biologics businesses. Dr. Kamarck also held numerous senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations, and Product Supply as a member of the Wyeth Management Team. While with Wyeth, he was responsible for establishing a global biotechnology network of more than 10,000 employees to develop and manufacture numerous blockbuster products, including building manufacturing facilities to deliver the global supply of Prevnar 13. Dr. Kamarck also spent 16 years at Bayer AG serving in numerous roles, including SVP of Operations for Bayer Biologicals. He has authored more than 50 peer-reviewed publications and has 20 issued patents.

Dr. Kamarck said, “Vaxcyte’s VAX-24 was designed to address the need for a PCV that can offer broader protection to prevent pneumococcal disease. As this program advances into clinical development, I look forward to sharing my knowledge about the worldwide commercialization and supply of vaccines, including PCVs.”

Dr. Kamarck received his B.A. from Oberlin College and his Ph.D. in biochemistry from the Massachusetts Institute of Technology.

About Vaxcyte

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum PCV being developed for the prevention of invasive pneumococcal disease. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team